Heather McArthur, MD
Medical Oncology · Dallas, TXNPI 1790940385
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Merck at 43.2% of the total. 2025 is the largest year on record at $81,219, 3.4 times the $23,828 reported in 2019. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $1185.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$136K
- Gilead$34K
- AstraZeneca$25K
- Pfizer$18K
- Astrazeneca UK Limited$16K
- Seagen Inc.$16K
- plus $69K from 17 others
Across 309 payments — averaging $23,597 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$5.3M
- AstraZeneca$1.1M
- Pfizer$403K
- Boston Scientific$252K
- Eli Lilly$103K
- Roche Products Limited$51K
- plus $58K from 3 others
What the payments were for
- Consulting fees$176,89256%
- Speaking & faculty fees$48,91416%
- Travel & lodging$82,62326%
- Food & beverage$5,6132%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 82 | $135,540 |
| Gilead | 24 | $33,808 |
| AstraZeneca | 26 | $25,480 |
| Pfizer(2 entities) | 14 | $18,211 |
| Astrazeneca UK Limited | 17 | $15,924 |
| Seagen Inc. | 20 | $15,786 |
| Novartis | 13 | $10,958 |
| Stemline Therapeutics Inc. | 14 | $9,118 |
| Boston Scientific | 9 | $8,933 |
| Puma Biotechnology, Inc. | 9 | $6,166 |
| Daiichi Sankyo Inc. | 9 | $5,526 |
| Lilly USA, LLC | 3 | $5,475 |
| E.r. Squibb & Sons, L.L.C. | 7 | $4,976 |
| Delcath Systems | 2 | $4,800 |
| Genentech USA, Inc. | 6 | $4,058 |
| Modernatx, Inc. | 1 | $2,746 |
| Eli Lilly | 2 | $2,200 |
| Beone Medicines USA, Inc. | 1 | $1,600 |
| Immunomedics, Inc. | 1 | $1,375 |
| Dr.reddy's Laboratories,inc. | 1 | $1,000 |
| Bristol Myers Squibb | 1 | $300 |
| Roche Products Limited | 2 | $84 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$314,079 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 31 | $587 |
| Prochlorperazine Maleate | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
- Kartik KonduriDallas$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.